Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + inotuzumab ozogamicin + gemcitabine + oxaliplatin
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a combination regimen consisting of four agents: - **Rituximab** is a monoclonal antibody targeting CD20 on B cells, leading to their depletion. It is widely used in the treatment of B-cell lymphomas. - **Inotuzumab ozogamicin** (previously known as CMC544) is an antibody-drug conjugate that targets CD22 on B cells and delivers a cytotoxic agent (calicheamicin), resulting in cell death. - **Gemcitabine** is a nucleoside analog (antimetabolite) that inhibits DNA synthesis and induces apoptosis. - **Oxaliplatin** is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis. The combination has been studied for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), particularly in patients not eligible for high-dose chemotherapy or autologous stem cell transplantation. The rationale for this regimen includes synergistic anti-tumor effects from targeting multiple pathways involved in lymphoma survival and proliferation[1][2][8].
- Other names
- R-GemOx plus CMC544rituximab plus inotuzumab ozogamicin plus gemcitabine and oxaliplatin
02
Targets
CD20 (B-lymphocyte antigen CD20)CD22 (Cluster of Differentiation 22)DNADNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on rituximab + inotuzumab ozogamicin + gemcitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + inotuzumab ozogamicin + gemcitabine + oxaliplatin.